Sanofi Free Cash Flow 2010-2023 | SNY
Sanofi annual/quarterly free cash flow history and growth rate from 2010 to 2023. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
- Sanofi free cash flow for the quarter ending December 31, 2023 was 8,927.89, a year-over-year.
- Sanofi free cash flow for the twelve months ending December 31, 2023 was , a year-over-year.
- Sanofi annual free cash flow for 2023 was $8.928B, a 13.65% decline from 2022.
- Sanofi annual free cash flow for 2022 was $10.339B, a 4.98% decline from 2021.
- Sanofi annual free cash flow for 2021 was $10.881B, a 52.33% increase from 2020.
| Sanofi Annual Free Cash Flow |
| 2023 |
8,927.89 |
| 2022 |
10,338.98 |
| 2021 |
10,880.97 |
| 2020 |
7,142.80 |
| 2019 |
8,010.24 |
| 2018 |
6,770.67 |
| 2017 |
6,734.33 |
| 2016 |
6,599.76 |
| 2015 |
6,361.48 |
| 2014 |
8,510.18 |
| 2013 |
7,923.31 |
| 2012 |
8,895.95 |
| 2011 |
10,997.55 |
| 2010 |
11,044.14 |
| 2009 |
9,504.19 |
| Sanofi Quarterly Free Cash Flow |
| 2023-12-31 |
8,927.89 |
| 2023-09-30 |
|
| 2023-06-30 |
3,501.27 |
| 2023-03-31 |
|
| 2022-12-31 |
10,338.98 |
| 2022-09-30 |
|
| 2022-06-30 |
|
| 2022-03-31 |
|
| 2021-09-30 |
|
| 2021-03-31 |
|
| 2020-09-30 |
|
| 2020-03-31 |
|
| 2019-09-30 |
|
| 2019-03-31 |
|
| 2018-03-31 |
|
| 2017-12-31 |
6,734.33 |
| 2017-09-30 |
|
| 2017-06-30 |
2,198.20 |
| 2017-03-31 |
|
| 2016-12-31 |
6,599.76 |
| 2016-09-30 |
|
| 2016-06-30 |
1,645.83 |
| 2016-03-31 |
|
| 2015-09-30 |
|
| 2015-06-30 |
2,834.08 |
| 2014-06-30 |
2,851.97 |
| 2013-06-30 |
2,095.97 |
| 2012-06-30 |
4,641.78 |
| 2012-03-31 |
|
| 2011-12-31 |
10,997.55 |
| 2011-09-30 |
|
| 2011-06-30 |
4,523.90 |
| 2011-03-31 |
|
| 2010-12-31 |
11,044.14 |
| 2010-09-30 |
|
| 2010-06-30 |
4,533.99 |
| 2010-03-31 |
|
| 2009-12-31 |
9,504.19 |
| 2009-09-30 |
|
| 2009-06-30 |
4,879.04 |
| 2009-03-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$123.116B |
$46.611B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
